F Ahmadi3,4, S Dashti-Khavidaki2,3,4, M R Khatami3,4, M Gatmiri3,4, F Ahmadi3,4, M Mahdavi-Mazdeh3,4, M T Najafi3,4, Z Foroozanfar5, A Mahdizadeh6, S Derafshi7. 1. Department of Pharmacotherapy, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran. 2. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. 3. Nephrology Research Center, Tehran University of Medical Sciences, Tehran, Iran. 4. Center of Excellence in Nephrology, Tehran University of Medical Sciences, Tehran, Iran. 5. Department of Epidemiology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 6. Faculty of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran. 7. Imam-Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
BACKGROUND: There is no treatment of choice for the management of acute antibody-mediated rejection (ABMR) in kidney transplant recipients. Plasmapheresis ± intravenous immunoglobulin (IVIg) ± rituximab has been used in different regimens with contradictory results. OBJECTIVE: To compare three regimens of acute ABMR management including plasmapheresis + IVIg ± rituximab in two different rituximab regimens. METHODS: In this prospective, observational study kidney transplant recipients with suspicious ABMR were categorized into three groups. Group 1 patients were treated with plasmapheresis + IVIg. Groups 2 and 3 received weekly rituximab at a dosage of 375 mg/m2 for either 4 doses (group 2 or high dose) or 2 doses (group 3 or low dose) in addition to plasmapheresis + IVIg. RESULTS: 8, 15, and 9 patients were categorized in groups 1, 2, and 3, respectively. There was no difference among the groups in terms of demographic and clinical characteristics of recipients and donors. Although, 1-year graft (37.5%, 60.0%, and 66.7% for groups 1, 2, and 3, respectively; p=0.308) and patients survival (75.0%, 86.7%, and 77.8% for groups 1, 2, and 3, respectively; p=0.730) were not significantly different among studied groups, graft survival was 22%-30% higher in rituximab-treated groups. Estimated glomerular filtration rate at 12th month of follow-up did not differ among groups (56.3±19.6, 57.3±20.6, 48.7±16.1 mL/min/1.73 m2 for groups 1, 2, and 3, respectively; p=0.683). However, kidney function steadily improved over time in rituximab-treated patients. CONCLUSION: Adding high or low doses of rituximab to plasmapheresis + IVIg comparably increased graft survival in suspicious acute ABMR kidney recipients and steadily improved kidney function among survived allografts over time.
BACKGROUND: There is no treatment of choice for the management of acute antibody-mediated rejection (ABMR) in kidney transplant recipients. Plasmapheresis ± intravenous immunoglobulin (IVIg) ± rituximab has been used in different regimens with contradictory results. OBJECTIVE: To compare three regimens of acute ABMR management including plasmapheresis + IVIg ± rituximab in two different rituximab regimens. METHODS: In this prospective, observational study kidney transplant recipients with suspicious ABMR were categorized into three groups. Group 1 patients were treated with plasmapheresis + IVIg. Groups 2 and 3 received weekly rituximab at a dosage of 375 mg/m2 for either 4 doses (group 2 or high dose) or 2 doses (group 3 or low dose) in addition to plasmapheresis + IVIg. RESULTS: 8, 15, and 9 patients were categorized in groups 1, 2, and 3, respectively. There was no difference among the groups in terms of demographic and clinical characteristics of recipients and donors. Although, 1-year graft (37.5%, 60.0%, and 66.7% for groups 1, 2, and 3, respectively; p=0.308) and patients survival (75.0%, 86.7%, and 77.8% for groups 1, 2, and 3, respectively; p=0.730) were not significantly different among studied groups, graft survival was 22%-30% higher in rituximab-treated groups. Estimated glomerular filtration rate at 12th month of follow-up did not differ among groups (56.3±19.6, 57.3±20.6, 48.7±16.1 mL/min/1.73 m2 for groups 1, 2, and 3, respectively; p=0.683). However, kidney function steadily improved over time in rituximab-treated patients. CONCLUSION: Adding high or low doses of rituximab to plasmapheresis + IVIg comparably increased graft survival in suspicious acute ABMR kidney recipients and steadily improved kidney function among survived allografts over time.
Authors: Robert A Montgomery; Mark A Hardy; Stanley C Jordan; Lorraine C Racusen; Lloyd E Ratner; Dolly B Tyan; Andrea A Zachary Journal: Transplantation Date: 2004-07-27 Impact factor: 4.939
Authors: Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: Nicole B White; Stuart M Greenstein; Alex W Cantafio; Richard Schechner; Daniel Glicklich; Patricia McDonough; James Pullman; Kala Mohandas; Fouad Boctor; Joan Uehlinger; Vivian Tellis Journal: Transplantation Date: 2004-09-15 Impact factor: 4.939
Authors: Paulo N Rocha; David W Butterly; Arthur Greenberg; Donal N Reddan; Janet Tuttle-Newhall; Bradley H Collins; Paul C Kuo; Nancy Reinsmoen; Timothy Fields; David N Howell; Stephen R Smith Journal: Transplantation Date: 2003-05-15 Impact factor: 4.939
Authors: G T Moscoso-Solorzano; J M Baltar; M Seco; C López-Larrea; G Mastroianni-Kirsztajn; F Ortega Journal: Transplant Proc Date: 2007-12 Impact factor: 1.066